ZS801
/ Sichuan Real & Best Biotech, Institute of Hematology and Blood Diseases Hospital
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 24, 2025
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
(clinicaltrials.gov)
- P=N/A | N=6 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting ➔ Recruiting | Trial primary completion date: Dec 2024 ➔ Dec 2025
Enrollment open • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia B • Rare Diseases
February 24, 2025
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
(clinicaltrials.gov)
- P1/2 | N=21 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Dec 2024 ➔ Dec 2025 | Not yet recruiting ➔ Recruiting
Enrollment open • Trial primary completion date • Hematological Disorders • Hemophilia • Hemophilia B • Rare Diseases
February 09, 2023
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
(clinicaltrials.gov)
- P1/2 | N=21 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital | Initiation date: Dec 2022 ➔ Mar 2023
Trial initiation date • Hematological Disorders • Hemophilia • Rare Diseases
December 07, 2022
A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
(clinicaltrials.gov)
- P1/2 | N=21 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital
New P1/2 trial • Hematological Disorders • Hemophilia • Rare Diseases
November 30, 2022
The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
(clinicaltrials.gov)
- P=N/A | N=6 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital
New trial • Hematological Disorders • Hemophilia • Rare Diseases
1 to 5
Of
5
Go to page
1